NIDA Notes Advanced Search

Researchers move their monoclonal antibody (mAb) into clinical trials to see if it can be an effective treatment for methamphetamine use.

Researchers have created a monoclonal antibody (mAb) that is intended to interact with methamphetamine and decrease its ability to enter the brain.

Neurogenesis that occurs during abstinence from methamphetamine in a brain region related to memory and learning may promote relapse-like behavior.

This study showed that rats will forgo heroin and methamphetamine in favor of spending time with another rat. It also highlights the importance of incorporating voluntary choice between drugs and social rewards in drug addiction research.

Dr. Linda Dwoskin wins a NIDA grant to continue her team's work to find a medication to treat methamphetamine addiction—but there's a string attached.

Los investigadores patrocinados por el NIDA mostraron que, en los monos, la metanfetamina altera las estructuras cerebrales involucradas en la toma de decisiones y afecta negativamente la capacidad de eliminar los comportamientos habituales que se han vuelto inútiles o contraproducentes.

Dr. Linda Dwoskin feels just one small step away from success in her effort to develop the first ever medication to treat methamphetamine addiction.

When lobeline turned out not to be the answer, it became a starting point. Dr. Linda Dwoskin and her team set out to transform the molecule into something more effective and with fewer side effects.